nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR4—prostate cancer	0.211	0.499	CbGaD
Ponatinib—FGFR2—prostate cancer	0.0769	0.182	CbGaD
Ponatinib—SRC—prostate cancer	0.0491	0.116	CbGaD
Ponatinib—KDR—prostate cancer	0.0461	0.109	CbGaD
Ponatinib—CYP3A5—prostate cancer	0.0278	0.0657	CbGaD
Ponatinib—ABCB11—Ethinyl Estradiol—prostate cancer	0.0269	0.0927	CbGbCtD
Ponatinib—ABCG2—Cabazitaxel—prostate cancer	0.0147	0.0506	CbGbCtD
Ponatinib—ABCG2—Estrone—prostate cancer	0.0144	0.0494	CbGbCtD
Ponatinib—CYP2C8—Nilutamide—prostate cancer	0.0128	0.044	CbGbCtD
Ponatinib—CYP3A4—prostate cancer	0.012	0.0285	CbGaD
Ponatinib—CYP3A5—Flutamide—prostate cancer	0.011	0.0379	CbGbCtD
Ponatinib—CYP2C8—Abiraterone—prostate cancer	0.0106	0.0364	CbGbCtD
Ponatinib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00987	0.0339	CbGbCtD
Ponatinib—ABCG2—Conjugated Estrogens—prostate cancer	0.0094	0.0323	CbGbCtD
Ponatinib—ABCG2—Mitoxantrone—prostate cancer	0.00855	0.0294	CbGbCtD
Ponatinib—ABCG2—Estradiol—prostate cancer	0.00825	0.0284	CbGbCtD
Ponatinib—CYP2D6—Bicalutamide—prostate cancer	0.00815	0.028	CbGbCtD
Ponatinib—CYP3A5—Cabazitaxel—prostate cancer	0.00815	0.028	CbGbCtD
Ponatinib—ABCB1—Estramustine—prostate cancer	0.00804	0.0277	CbGbCtD
Ponatinib—CYP3A5—Estrone—prostate cancer	0.00796	0.0274	CbGbCtD
Ponatinib—CYP2C8—Cabazitaxel—prostate cancer	0.00783	0.0269	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—prostate cancer	0.00773	0.0266	CbGbCtD
Ponatinib—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00682	0.0235	CbGbCtD
Ponatinib—CYP2D6—Abiraterone—prostate cancer	0.00675	0.0232	CbGbCtD
Ponatinib—ABCG2—Etoposide—prostate cancer	0.00539	0.0185	CbGbCtD
Ponatinib—ABCB1—Cabazitaxel—prostate cancer	0.0053	0.0182	CbGbCtD
Ponatinib—CYP3A4—Bicalutamide—prostate cancer	0.00518	0.0178	CbGbCtD
Ponatinib—ABCB1—Estrone—prostate cancer	0.00518	0.0178	CbGbCtD
Ponatinib—ABCG2—Docetaxel—prostate cancer	0.00493	0.017	CbGbCtD
Ponatinib—CYP3A4—Estramustine—prostate cancer	0.00482	0.0166	CbGbCtD
Ponatinib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00462	0.0159	CbGbCtD
Ponatinib—CYP3A5—Estradiol—prostate cancer	0.00457	0.0157	CbGbCtD
Ponatinib—CYP2C8—Estradiol—prostate cancer	0.0044	0.0151	CbGbCtD
Ponatinib—CYP3A4—Flutamide—prostate cancer	0.00429	0.0148	CbGbCtD
Ponatinib—CYP3A4—Abiraterone—prostate cancer	0.00429	0.0148	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—prostate cancer	0.00368	0.0126	CbGbCtD
Ponatinib—ABCB1—Conjugated Estrogens—prostate cancer	0.00339	0.0117	CbGbCtD
Ponatinib—CYP3A4—Cabazitaxel—prostate cancer	0.00318	0.0109	CbGbCtD
Ponatinib—CYP3A4—Estrone—prostate cancer	0.0031	0.0107	CbGbCtD
Ponatinib—ABCB1—Mitoxantrone—prostate cancer	0.00308	0.0106	CbGbCtD
Ponatinib—CYP3A5—Etoposide—prostate cancer	0.00299	0.0103	CbGbCtD
Ponatinib—ABCB1—Estradiol—prostate cancer	0.00298	0.0102	CbGbCtD
Ponatinib—PDGFRA—penis—prostate cancer	0.00289	0.0617	CbGeAlD
Ponatinib—CYP2C8—Etoposide—prostate cancer	0.00287	0.00988	CbGbCtD
Ponatinib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00277	0.00952	CbGbCtD
Ponatinib—CYP3A5—Docetaxel—prostate cancer	0.00273	0.0094	CbGbCtD
Ponatinib—ABCB1—Prednisone—prostate cancer	0.00256	0.00881	CbGbCtD
Ponatinib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00203	0.00699	CbGbCtD
Ponatinib—ABCB1—Etoposide—prostate cancer	0.00194	0.00669	CbGbCtD
Ponatinib—CYP3A4—Mitoxantrone—prostate cancer	0.00185	0.00635	CbGbCtD
Ponatinib—CYP3A4—Estradiol—prostate cancer	0.00178	0.00614	CbGbCtD
Ponatinib—ABCB1—Docetaxel—prostate cancer	0.00178	0.00612	CbGbCtD
Ponatinib—FGFR4—prostate gland—prostate cancer	0.00178	0.038	CbGeAlD
Ponatinib—CYP3A4—Prednisone—prostate cancer	0.00153	0.00528	CbGbCtD
Ponatinib—ABCB1—Doxorubicin—prostate cancer	0.00133	0.00456	CbGbCtD
Ponatinib—Nilotinib—EPHB2—prostate cancer	0.00132	0.472	CrCbGaD
Ponatinib—CYP2D6—Doxorubicin—prostate cancer	0.00125	0.0043	CbGbCtD
Ponatinib—FGFR3—prostate gland—prostate cancer	0.00121	0.0259	CbGeAlD
Ponatinib—FGFR4—renal system—prostate cancer	0.00121	0.0259	CbGeAlD
Ponatinib—CYP3A4—Etoposide—prostate cancer	0.00116	0.00401	CbGbCtD
Ponatinib—CYP3A4—Docetaxel—prostate cancer	0.00107	0.00367	CbGbCtD
Ponatinib—BCR—prostate gland—prostate cancer	0.00105	0.0224	CbGeAlD
Ponatinib—FGFR1—prostate gland—prostate cancer	0.000934	0.0199	CbGeAlD
Ponatinib—FGFR3—epithelium—prostate cancer	0.000891	0.019	CbGeAlD
Ponatinib—BCR—seminal vesicle—prostate cancer	0.000888	0.019	CbGeAlD
Ponatinib—RET—prostate gland—prostate cancer	0.000835	0.0178	CbGeAlD
Ponatinib—LCK—prostate gland—prostate cancer	0.000835	0.0178	CbGeAlD
Ponatinib—FGFR3—renal system—prostate cancer	0.000827	0.0177	CbGeAlD
Ponatinib—FGFR3—urethra—prostate cancer	0.000812	0.0173	CbGeAlD
Ponatinib—CYP3A4—Doxorubicin—prostate cancer	0.000794	0.00273	CbGbCtD
Ponatinib—FGFR2—prostate gland—prostate cancer	0.000794	0.017	CbGeAlD
Ponatinib—FGFR4—testis—prostate cancer	0.000783	0.0167	CbGeAlD
Ponatinib—TEK—prostate gland—prostate cancer	0.000761	0.0163	CbGeAlD
Ponatinib—BCR—renal system—prostate cancer	0.000715	0.0153	CbGeAlD
Ponatinib—BCR—urethra—prostate cancer	0.000703	0.015	CbGeAlD
Ponatinib—PDGFRA—prostate gland—prostate cancer	0.00069	0.0147	CbGeAlD
Ponatinib—SRC—prostate gland—prostate cancer	0.000676	0.0144	CbGeAlD
Ponatinib—FGFR1—urethra—prostate cancer	0.000625	0.0134	CbGeAlD
Ponatinib—KDR—prostate gland—prostate cancer	0.000622	0.0133	CbGeAlD
Ponatinib—RET—epithelium—prostate cancer	0.000614	0.0131	CbGeAlD
Ponatinib—CYP3A4—urine—prostate cancer	0.000587	0.0125	CbGeAlD
Ponatinib—FGFR2—epithelium—prostate cancer	0.000583	0.0125	CbGeAlD
Ponatinib—CYP2D6—urine—prostate cancer	0.000578	0.0123	CbGeAlD
Ponatinib—RET—renal system—prostate cancer	0.000569	0.0122	CbGeAlD
Ponatinib—FGFR4—lymph node—prostate cancer	0.000568	0.0121	CbGeAlD
Ponatinib—LCK—urethra—prostate cancer	0.000559	0.0119	CbGeAlD
Ponatinib—TEK—epithelium—prostate cancer	0.000559	0.0119	CbGeAlD
Ponatinib—KIT—prostate gland—prostate cancer	0.000551	0.0118	CbGeAlD
Ponatinib—FGFR2—renal system—prostate cancer	0.000541	0.0116	CbGeAlD
Ponatinib—BCR—bone marrow—prostate cancer	0.000541	0.0116	CbGeAlD
Ponatinib—FLT3—bone marrow—prostate cancer	0.000537	0.0115	CbGeAlD
Ponatinib—FGFR3—testis—prostate cancer	0.000534	0.0114	CbGeAlD
Ponatinib—KDR—seminal vesicle—prostate cancer	0.000526	0.0112	CbGeAlD
Ponatinib—TEK—renal system—prostate cancer	0.000519	0.0111	CbGeAlD
Ponatinib—TEK—urethra—prostate cancer	0.00051	0.0109	CbGeAlD
Ponatinib—SRC—epithelium—prostate cancer	0.000497	0.0106	CbGeAlD
Ponatinib—ABL1—prostate gland—prostate cancer	0.00048	0.0103	CbGeAlD
Ponatinib—FGFR4—Podofilox—Etoposide—prostate cancer	0.000479	0.214	CbGdCrCtD
Ponatinib—PDGFRA—renal system—prostate cancer	0.00047	0.01	CbGeAlD
Ponatinib—KIT—seminal vesicle—prostate cancer	0.000466	0.00996	CbGeAlD
Ponatinib—BCR—testis—prostate cancer	0.000462	0.00987	CbGeAlD
Ponatinib—SRC—renal system—prostate cancer	0.000461	0.00985	CbGeAlD
Ponatinib—FLT3—testis—prostate cancer	0.000459	0.00981	CbGeAlD
Ponatinib—KDR—epithelium—prostate cancer	0.000457	0.00976	CbGeAlD
Ponatinib—Nilotinib—PDGFRB—prostate cancer	0.000448	0.16	CrCbGaD
Ponatinib—LCK—bone marrow—prostate cancer	0.000431	0.0092	CbGeAlD
Ponatinib—KDR—renal system—prostate cancer	0.000424	0.00906	CbGeAlD
Ponatinib—KDR—urethra—prostate cancer	0.000416	0.0089	CbGeAlD
Ponatinib—FGFR1—testis—prostate cancer	0.000411	0.00879	CbGeAlD
Ponatinib—ABL1—seminal vesicle—prostate cancer	0.000406	0.00867	CbGeAlD
Ponatinib—KIT—epithelium—prostate cancer	0.000405	0.00865	CbGeAlD
Ponatinib—KIT—renal system—prostate cancer	0.000376	0.00803	CbGeAlD
Ponatinib—Imatinib—PDGFRB—prostate cancer	0.000373	0.133	CrCbGaD
Ponatinib—KIT—urethra—prostate cancer	0.000369	0.00788	CbGeAlD
Ponatinib—LCK—testis—prostate cancer	0.000368	0.00786	CbGeAlD
Ponatinib—RET—testis—prostate cancer	0.000368	0.00786	CbGeAlD
Ponatinib—ABCB11—testis—prostate cancer	0.000359	0.00768	CbGeAlD
Ponatinib—FGFR2—testis—prostate cancer	0.00035	0.00747	CbGeAlD
Ponatinib—FGFR2—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000336	0.15	CbGdCrCtD
Ponatinib—TEK—testis—prostate cancer	0.000335	0.00716	CbGeAlD
Ponatinib—BCR—lymph node—prostate cancer	0.000335	0.00716	CbGeAlD
Ponatinib—FLT3—lymph node—prostate cancer	0.000333	0.00711	CbGeAlD
Ponatinib—ABL1—renal system—prostate cancer	0.000327	0.00699	CbGeAlD
Ponatinib—ABL1—urethra—prostate cancer	0.000321	0.00686	CbGeAlD
Ponatinib—KDR—bone marrow—prostate cancer	0.000321	0.00685	CbGeAlD
Ponatinib—PDGFRA—testis—prostate cancer	0.000304	0.00649	CbGeAlD
Ponatinib—ABCG2—prostate gland—prostate cancer	0.000303	0.00646	CbGeAlD
Ponatinib—FGFR1—lymph node—prostate cancer	0.000298	0.00637	CbGeAlD
Ponatinib—SRC—testis—prostate cancer	0.000298	0.00636	CbGeAlD
Ponatinib—FGFR2—Estradiol—Estramustine—prostate cancer	0.000286	0.128	CbGdCrCtD
Ponatinib—KIT—bone marrow—prostate cancer	0.000284	0.00607	CbGeAlD
Ponatinib—CYP3A5—prostate gland—prostate cancer	0.000281	0.006	CbGeAlD
Ponatinib—KDR—testis—prostate cancer	0.000274	0.00585	CbGeAlD
Ponatinib—RET—lymph node—prostate cancer	0.000267	0.0057	CbGeAlD
Ponatinib—LCK—lymph node—prostate cancer	0.000267	0.0057	CbGeAlD
Ponatinib—ABCG2—seminal vesicle—prostate cancer	0.000256	0.00547	CbGeAlD
Ponatinib—ABL1—bone marrow—prostate cancer	0.000247	0.00528	CbGeAlD
Ponatinib—TEK—lymph node—prostate cancer	0.000243	0.00519	CbGeAlD
Ponatinib—KIT—testis—prostate cancer	0.000243	0.00519	CbGeAlD
Ponatinib—FGFR2—Estradiol—Estrone—prostate cancer	0.000227	0.101	CbGdCrCtD
Ponatinib—PDGFRA—lymph node—prostate cancer	0.00022	0.0047	CbGeAlD
Ponatinib—SRC—lymph node—prostate cancer	0.000216	0.00461	CbGeAlD
Ponatinib—CYP2C8—renal system—prostate cancer	0.000212	0.00453	CbGeAlD
Ponatinib—Imatinib—SLC22A1—prostate cancer	0.000212	0.0755	CrCbGaD
Ponatinib—ABL1—testis—prostate cancer	0.000211	0.00452	CbGeAlD
Ponatinib—ABCG2—urethra—prostate cancer	0.000203	0.00433	CbGeAlD
Ponatinib—FGFR2—Estradiol—Conjugated Estrogens—prostate cancer	0.0002	0.0894	CbGdCrCtD
Ponatinib—KDR—lymph node—prostate cancer	0.000199	0.00424	CbGeAlD
Ponatinib—CYP3A5—renal system—prostate cancer	0.000191	0.00409	CbGeAlD
Ponatinib—KIT—lymph node—prostate cancer	0.000176	0.00376	CbGeAlD
Ponatinib—Imatinib—CYP3A5—prostate cancer	0.000171	0.0609	CrCbGaD
Ponatinib—FGFR2—Estradiol—Ethinyl Estradiol—prostate cancer	0.000168	0.0751	CbGdCrCtD
Ponatinib—ABCG2—bone marrow—prostate cancer	0.000156	0.00333	CbGeAlD
Ponatinib—ABL1—lymph node—prostate cancer	0.000153	0.00327	CbGeAlD
Ponatinib—ABCB1—prostate gland—prostate cancer	0.000149	0.00319	CbGeAlD
Ponatinib—CYP3A4—renal system—prostate cancer	0.000144	0.00307	CbGeAlD
Ponatinib—CYP2D6—renal system—prostate cancer	0.000141	0.00302	CbGeAlD
Ponatinib—CYP2C8—testis—prostate cancer	0.000137	0.00293	CbGeAlD
Ponatinib—ABCG2—testis—prostate cancer	0.000133	0.00285	CbGeAlD
Ponatinib—ABCB1—seminal vesicle—prostate cancer	0.000126	0.0027	CbGeAlD
Ponatinib—Imatinib—CYP2C19—prostate cancer	0.000116	0.0415	CrCbGaD
Ponatinib—ABL1—Levorphanol—Estrone—prostate cancer	0.000113	0.0505	CbGdCrCtD
Ponatinib—ABCB1—epithelium—prostate cancer	0.00011	0.00234	CbGeAlD
Ponatinib—ABCB1—renal system—prostate cancer	0.000102	0.00217	CbGeAlD
Ponatinib—ABCB1—urethra—prostate cancer	9.99e-05	0.00213	CbGeAlD
Ponatinib—ABCG2—lymph node—prostate cancer	9.66e-05	0.00206	CbGeAlD
Ponatinib—CYP2D6—testis—prostate cancer	9.14e-05	0.00195	CbGeAlD
Ponatinib—Nilotinib—CYP3A4—prostate cancer	8.86e-05	0.0316	CrCbGaD
Ponatinib—ABL1—Levorphanol—Estradiol—prostate cancer	8.57e-05	0.0383	CbGdCrCtD
Ponatinib—ABCB1—bone marrow—prostate cancer	7.69e-05	0.00164	CbGeAlD
Ponatinib—Imatinib—CYP3A4—prostate cancer	7.39e-05	0.0264	CrCbGaD
Ponatinib—ABCB1—testis—prostate cancer	6.57e-05	0.0014	CbGeAlD
Ponatinib—ABL1—Doxorubicin—Epirubicin—prostate cancer	5.95e-05	0.0266	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Epirubicin—prostate cancer	5.95e-05	0.0266	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Epirubicin—prostate cancer	5.95e-05	0.0266	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Doxorubicin—prostate cancer	5.51e-05	0.0246	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Doxorubicin—prostate cancer	5.51e-05	0.0246	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—prostate cancer	5.51e-05	0.0246	CbGdCrCtD
Ponatinib—ABCB1—lymph node—prostate cancer	4.76e-05	0.00102	CbGeAlD
Ponatinib—Neuropathy peripheral—Epirubicin—prostate cancer	2.32e-05	0.000196	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	2.32e-05	0.000196	CcSEcCtD
Ponatinib—Cough—Capecitabine—prostate cancer	2.32e-05	0.000196	CcSEcCtD
Ponatinib—Jaundice—Epirubicin—prostate cancer	2.31e-05	0.000195	CcSEcCtD
Ponatinib—Stomatitis—Epirubicin—prostate cancer	2.31e-05	0.000195	CcSEcCtD
Ponatinib—Constipation—Etoposide—prostate cancer	2.3e-05	0.000195	CcSEcCtD
Ponatinib—Pain—Etoposide—prostate cancer	2.3e-05	0.000195	CcSEcCtD
Ponatinib—Urinary tract infection—Epirubicin—prostate cancer	2.3e-05	0.000195	CcSEcCtD
Ponatinib—Dizziness—Estradiol—prostate cancer	2.3e-05	0.000194	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—prostate cancer	2.3e-05	0.000194	CcSEcCtD
Ponatinib—Hypertension—Capecitabine—prostate cancer	2.29e-05	0.000194	CcSEcCtD
Ponatinib—Dry mouth—Docetaxel—prostate cancer	2.28e-05	0.000193	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—prostate cancer	2.28e-05	0.000193	CcSEcCtD
Ponatinib—Arthralgia—Capecitabine—prostate cancer	2.26e-05	0.000191	CcSEcCtD
Ponatinib—Myalgia—Capecitabine—prostate cancer	2.26e-05	0.000191	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	2.24e-05	0.00019	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—prostate cancer	2.24e-05	0.000189	CcSEcCtD
Ponatinib—Oedema—Docetaxel—prostate cancer	2.24e-05	0.000189	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—prostate cancer	2.23e-05	0.000189	CcSEcCtD
Ponatinib—Vision blurred—Prednisone—prostate cancer	2.23e-05	0.000189	CcSEcCtD
Ponatinib—Infection—Docetaxel—prostate cancer	2.22e-05	0.000188	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—prostate cancer	2.22e-05	0.000188	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—prostate cancer	2.22e-05	0.000187	CcSEcCtD
Ponatinib—Diarrhoea—Mitoxantrone—prostate cancer	2.21e-05	0.000187	CcSEcCtD
Ponatinib—Dry mouth—Capecitabine—prostate cancer	2.21e-05	0.000187	CcSEcCtD
Ponatinib—Vomiting—Estradiol—prostate cancer	2.21e-05	0.000187	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—prostate cancer	2.2e-05	0.000186	CcSEcCtD
Ponatinib—Gastrointestinal pain—Etoposide—prostate cancer	2.2e-05	0.000186	CcSEcCtD
Ponatinib—Nervous system disorder—Docetaxel—prostate cancer	2.19e-05	0.000186	CcSEcCtD
Ponatinib—Thrombocytopenia—Docetaxel—prostate cancer	2.19e-05	0.000185	CcSEcCtD
Ponatinib—Rash—Estradiol—prostate cancer	2.19e-05	0.000185	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—prostate cancer	2.19e-05	0.000185	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—prostate cancer	2.19e-05	0.000185	CcSEcCtD
Ponatinib—Dermatitis—Estradiol—prostate cancer	2.19e-05	0.000185	CcSEcCtD
Ponatinib—Anaemia—Prednisone—prostate cancer	2.19e-05	0.000185	CcSEcCtD
Ponatinib—Headache—Estradiol—prostate cancer	2.18e-05	0.000184	CcSEcCtD
Ponatinib—Skin disorder—Docetaxel—prostate cancer	2.17e-05	0.000184	CcSEcCtD
Ponatinib—Oedema—Capecitabine—prostate cancer	2.17e-05	0.000183	CcSEcCtD
Ponatinib—Infection—Capecitabine—prostate cancer	2.15e-05	0.000182	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—prostate cancer	2.15e-05	0.000182	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—prostate cancer	2.14e-05	0.000181	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—prostate cancer	2.13e-05	0.000181	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—prostate cancer	2.13e-05	0.000181	CcSEcCtD
Ponatinib—Abdominal pain—Etoposide—prostate cancer	2.13e-05	0.00018	CcSEcCtD
Ponatinib—Body temperature increased—Etoposide—prostate cancer	2.13e-05	0.00018	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—prostate cancer	2.13e-05	0.00018	CcSEcCtD
Ponatinib—Nervous system disorder—Capecitabine—prostate cancer	2.12e-05	0.00018	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—prostate cancer	2.12e-05	0.00018	CcSEcCtD
Ponatinib—Thrombocytopenia—Capecitabine—prostate cancer	2.12e-05	0.000179	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—prostate cancer	2.11e-05	0.000179	CcSEcCtD
Ponatinib—Skin disorder—Capecitabine—prostate cancer	2.1e-05	0.000178	CcSEcCtD
Ponatinib—Hyperhidrosis—Capecitabine—prostate cancer	2.09e-05	0.000177	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—prostate cancer	2.09e-05	0.000177	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—prostate cancer	2.09e-05	0.000177	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—prostate cancer	2.07e-05	0.000175	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—prostate cancer	2.07e-05	0.000175	CcSEcCtD
Ponatinib—Nausea—Estradiol—prostate cancer	2.06e-05	0.000175	CcSEcCtD
Ponatinib—Vomiting—Mitoxantrone—prostate cancer	2.06e-05	0.000174	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—prostate cancer	2.05e-05	0.000173	CcSEcCtD
Ponatinib—Hypertension—Prednisone—prostate cancer	2.04e-05	0.000173	CcSEcCtD
Ponatinib—Rash—Mitoxantrone—prostate cancer	2.04e-05	0.000173	CcSEcCtD
Ponatinib—Dermatitis—Mitoxantrone—prostate cancer	2.04e-05	0.000172	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.04e-05	0.000172	CcSEcCtD
Ponatinib—Headache—Mitoxantrone—prostate cancer	2.03e-05	0.000172	CcSEcCtD
Ponatinib—Insomnia—Docetaxel—prostate cancer	2.02e-05	0.000171	CcSEcCtD
Ponatinib—Myalgia—Prednisone—prostate cancer	2.01e-05	0.00017	CcSEcCtD
Ponatinib—Arthralgia—Prednisone—prostate cancer	2.01e-05	0.00017	CcSEcCtD
Ponatinib—Paraesthesia—Docetaxel—prostate cancer	2.01e-05	0.00017	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2e-05	0.000169	CcSEcCtD
Ponatinib—Dyspnoea—Docetaxel—prostate cancer	2e-05	0.000169	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—prostate cancer	1.99e-05	0.000168	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—prostate cancer	1.98e-05	0.000167	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Capecitabine—prostate cancer	1.97e-05	0.000167	CcSEcCtD
Ponatinib—Flushing—Epirubicin—prostate cancer	1.97e-05	0.000167	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—prostate cancer	1.97e-05	0.000167	CcSEcCtD
Ponatinib—Dyspepsia—Docetaxel—prostate cancer	1.97e-05	0.000167	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—prostate cancer	1.97e-05	0.000166	CcSEcCtD
Ponatinib—Insomnia—Capecitabine—prostate cancer	1.96e-05	0.000166	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—prostate cancer	1.96e-05	0.000165	CcSEcCtD
Ponatinib—Paraesthesia—Capecitabine—prostate cancer	1.95e-05	0.000165	CcSEcCtD
Ponatinib—Decreased appetite—Docetaxel—prostate cancer	1.95e-05	0.000165	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—prostate cancer	1.94e-05	0.000164	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Docetaxel—prostate cancer	1.93e-05	0.000163	CcSEcCtD
Ponatinib—Asthenia—Etoposide—prostate cancer	1.93e-05	0.000163	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—prostate cancer	1.93e-05	0.000163	CcSEcCtD
Ponatinib—Dyspnoea—Capecitabine—prostate cancer	1.93e-05	0.000163	CcSEcCtD
Ponatinib—Oedema—Prednisone—prostate cancer	1.93e-05	0.000163	CcSEcCtD
Ponatinib—Fatigue—Docetaxel—prostate cancer	1.93e-05	0.000163	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—prostate cancer	1.93e-05	0.000163	CcSEcCtD
Ponatinib—Nausea—Mitoxantrone—prostate cancer	1.92e-05	0.000163	CcSEcCtD
Ponatinib—Infection—Prednisone—prostate cancer	1.92e-05	0.000162	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—prostate cancer	1.91e-05	0.000162	CcSEcCtD
Ponatinib—Constipation—Docetaxel—prostate cancer	1.91e-05	0.000162	CcSEcCtD
Ponatinib—Pain—Docetaxel—prostate cancer	1.91e-05	0.000162	CcSEcCtD
Ponatinib—Dyspepsia—Capecitabine—prostate cancer	1.91e-05	0.000161	CcSEcCtD
Ponatinib—Chills—Epirubicin—prostate cancer	1.91e-05	0.000161	CcSEcCtD
Ponatinib—Pruritus—Etoposide—prostate cancer	1.91e-05	0.000161	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—prostate cancer	1.9e-05	0.000161	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—prostate cancer	1.89e-05	0.00016	CcSEcCtD
Ponatinib—Nervous system disorder—Prednisone—prostate cancer	1.89e-05	0.00016	CcSEcCtD
Ponatinib—Decreased appetite—Capecitabine—prostate cancer	1.88e-05	0.000159	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—prostate cancer	1.88e-05	0.000159	CcSEcCtD
Ponatinib—Skin disorder—Prednisone—prostate cancer	1.87e-05	0.000159	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Capecitabine—prostate cancer	1.87e-05	0.000158	CcSEcCtD
Ponatinib—Fatigue—Capecitabine—prostate cancer	1.87e-05	0.000158	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisone—prostate cancer	1.87e-05	0.000158	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—prostate cancer	1.86e-05	0.000157	CcSEcCtD
Ponatinib—Pain—Capecitabine—prostate cancer	1.85e-05	0.000157	CcSEcCtD
Ponatinib—Constipation—Capecitabine—prostate cancer	1.85e-05	0.000157	CcSEcCtD
Ponatinib—Erythema—Epirubicin—prostate cancer	1.85e-05	0.000156	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—prostate cancer	1.85e-05	0.000156	CcSEcCtD
Ponatinib—Diarrhoea—Etoposide—prostate cancer	1.84e-05	0.000156	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—prostate cancer	1.84e-05	0.000155	CcSEcCtD
Ponatinib—Gastrointestinal pain—Docetaxel—prostate cancer	1.83e-05	0.000155	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—prostate cancer	1.82e-05	0.000154	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—prostate cancer	1.82e-05	0.000154	CcSEcCtD
Ponatinib—Back pain—Epirubicin—prostate cancer	1.79e-05	0.000151	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—prostate cancer	1.78e-05	0.000151	CcSEcCtD
Ponatinib—Dizziness—Etoposide—prostate cancer	1.78e-05	0.000151	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—prostate cancer	1.78e-05	0.00015	CcSEcCtD
Ponatinib—Gastrointestinal pain—Capecitabine—prostate cancer	1.77e-05	0.00015	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—prostate cancer	1.77e-05	0.00015	CcSEcCtD
Ponatinib—Abdominal pain—Docetaxel—prostate cancer	1.77e-05	0.00015	CcSEcCtD
Ponatinib—Body temperature increased—Docetaxel—prostate cancer	1.77e-05	0.00015	CcSEcCtD
Ponatinib—Chills—Doxorubicin—prostate cancer	1.76e-05	0.000149	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Prednisone—prostate cancer	1.76e-05	0.000149	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—prostate cancer	1.76e-05	0.000149	CcSEcCtD
Ponatinib—Insomnia—Prednisone—prostate cancer	1.75e-05	0.000148	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—prostate cancer	1.74e-05	0.000147	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—prostate cancer	1.74e-05	0.000147	CcSEcCtD
Ponatinib—Paraesthesia—Prednisone—prostate cancer	1.73e-05	0.000147	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—prostate cancer	1.72e-05	0.000146	CcSEcCtD
Ponatinib—Body temperature increased—Capecitabine—prostate cancer	1.71e-05	0.000145	CcSEcCtD
Ponatinib—Abdominal pain—Capecitabine—prostate cancer	1.71e-05	0.000145	CcSEcCtD
Ponatinib—Vomiting—Etoposide—prostate cancer	1.71e-05	0.000145	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—prostate cancer	1.71e-05	0.000145	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—prostate cancer	1.71e-05	0.000145	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—prostate cancer	1.71e-05	0.000145	CcSEcCtD
Ponatinib—Dyspepsia—Prednisone—prostate cancer	1.7e-05	0.000144	CcSEcCtD
Ponatinib—Rash—Etoposide—prostate cancer	1.7e-05	0.000144	CcSEcCtD
Ponatinib—Dermatitis—Etoposide—prostate cancer	1.7e-05	0.000143	CcSEcCtD
Ponatinib—Headache—Etoposide—prostate cancer	1.69e-05	0.000143	CcSEcCtD
Ponatinib—Decreased appetite—Prednisone—prostate cancer	1.68e-05	0.000142	CcSEcCtD
Ponatinib—Fatigue—Prednisone—prostate cancer	1.66e-05	0.000141	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—prostate cancer	1.66e-05	0.00014	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—prostate cancer	1.66e-05	0.00014	CcSEcCtD
Ponatinib—Constipation—Prednisone—prostate cancer	1.65e-05	0.00014	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—prostate cancer	1.65e-05	0.000139	CcSEcCtD
Ponatinib—Cough—Epirubicin—prostate cancer	1.61e-05	0.000137	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—prostate cancer	1.61e-05	0.000136	CcSEcCtD
Ponatinib—Asthenia—Docetaxel—prostate cancer	1.61e-05	0.000136	CcSEcCtD
Ponatinib—Nausea—Etoposide—prostate cancer	1.6e-05	0.000135	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—prostate cancer	1.6e-05	0.000135	CcSEcCtD
Ponatinib—Pruritus—Docetaxel—prostate cancer	1.58e-05	0.000134	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—prostate cancer	1.58e-05	0.000134	CcSEcCtD
Ponatinib—Gastrointestinal pain—Prednisone—prostate cancer	1.58e-05	0.000133	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—prostate cancer	1.57e-05	0.000133	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—prostate cancer	1.57e-05	0.000133	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.56e-05	0.000132	CcSEcCtD
Ponatinib—Asthenia—Capecitabine—prostate cancer	1.55e-05	0.000131	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—prostate cancer	1.54e-05	0.00013	CcSEcCtD
Ponatinib—Pruritus—Capecitabine—prostate cancer	1.53e-05	0.00013	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—prostate cancer	1.53e-05	0.00013	CcSEcCtD
Ponatinib—Diarrhoea—Docetaxel—prostate cancer	1.53e-05	0.00013	CcSEcCtD
Ponatinib—Abdominal pain—Prednisone—prostate cancer	1.53e-05	0.000129	CcSEcCtD
Ponatinib—Body temperature increased—Prednisone—prostate cancer	1.53e-05	0.000129	CcSEcCtD
Ponatinib—Oedema—Epirubicin—prostate cancer	1.51e-05	0.000128	CcSEcCtD
Ponatinib—Infection—Epirubicin—prostate cancer	1.5e-05	0.000127	CcSEcCtD
Ponatinib—Cough—Doxorubicin—prostate cancer	1.49e-05	0.000126	CcSEcCtD
Ponatinib—Diarrhoea—Capecitabine—prostate cancer	1.48e-05	0.000125	CcSEcCtD
Ponatinib—Nervous system disorder—Epirubicin—prostate cancer	1.48e-05	0.000125	CcSEcCtD
Ponatinib—Dizziness—Docetaxel—prostate cancer	1.48e-05	0.000125	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—prostate cancer	1.48e-05	0.000125	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—prostate cancer	1.48e-05	0.000125	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—prostate cancer	1.47e-05	0.000124	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—prostate cancer	1.46e-05	0.000123	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—prostate cancer	1.46e-05	0.000123	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—prostate cancer	1.46e-05	0.000123	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.45e-05	0.000122	CcSEcCtD
Ponatinib—Dizziness—Capecitabine—prostate cancer	1.43e-05	0.000121	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—prostate cancer	1.42e-05	0.000121	CcSEcCtD
Ponatinib—Vomiting—Docetaxel—prostate cancer	1.42e-05	0.00012	CcSEcCtD
Ponatinib—Rash—Docetaxel—prostate cancer	1.41e-05	0.000119	CcSEcCtD
Ponatinib—Dermatitis—Docetaxel—prostate cancer	1.41e-05	0.000119	CcSEcCtD
Ponatinib—Headache—Docetaxel—prostate cancer	1.4e-05	0.000119	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—prostate cancer	1.4e-05	0.000118	CcSEcCtD
Ponatinib—Infection—Doxorubicin—prostate cancer	1.39e-05	0.000117	CcSEcCtD
Ponatinib—Asthenia—Prednisone—prostate cancer	1.38e-05	0.000117	CcSEcCtD
Ponatinib—Vomiting—Capecitabine—prostate cancer	1.38e-05	0.000117	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.38e-05	0.000116	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—prostate cancer	1.37e-05	0.000116	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—prostate cancer	1.37e-05	0.000116	CcSEcCtD
Ponatinib—Rash—Capecitabine—prostate cancer	1.37e-05	0.000116	CcSEcCtD
Ponatinib—Pruritus—Prednisone—prostate cancer	1.37e-05	0.000115	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—prostate cancer	1.37e-05	0.000115	CcSEcCtD
Ponatinib—Dermatitis—Capecitabine—prostate cancer	1.36e-05	0.000115	CcSEcCtD
Ponatinib—Headache—Capecitabine—prostate cancer	1.36e-05	0.000115	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—prostate cancer	1.36e-05	0.000115	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—prostate cancer	1.36e-05	0.000115	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—prostate cancer	1.35e-05	0.000114	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—prostate cancer	1.35e-05	0.000114	CcSEcCtD
Ponatinib—Nausea—Docetaxel—prostate cancer	1.33e-05	0.000112	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—prostate cancer	1.33e-05	0.000112	CcSEcCtD
Ponatinib—Diarrhoea—Prednisone—prostate cancer	1.32e-05	0.000112	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—prostate cancer	1.31e-05	0.000111	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—prostate cancer	1.3e-05	0.00011	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—prostate cancer	1.3e-05	0.00011	CcSEcCtD
Ponatinib—Constipation—Epirubicin—prostate cancer	1.29e-05	0.000109	CcSEcCtD
Ponatinib—Pain—Epirubicin—prostate cancer	1.29e-05	0.000109	CcSEcCtD
Ponatinib—Nausea—Capecitabine—prostate cancer	1.29e-05	0.000109	CcSEcCtD
Ponatinib—Dizziness—Prednisone—prostate cancer	1.28e-05	0.000108	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.27e-05	0.000108	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—prostate cancer	1.26e-05	0.000107	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—prostate cancer	1.25e-05	0.000106	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—prostate cancer	1.25e-05	0.000105	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—prostate cancer	1.23e-05	0.000104	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—prostate cancer	1.23e-05	0.000104	CcSEcCtD
Ponatinib—Vomiting—Prednisone—prostate cancer	1.23e-05	0.000104	CcSEcCtD
Ponatinib—Rash—Prednisone—prostate cancer	1.22e-05	0.000103	CcSEcCtD
Ponatinib—Dermatitis—Prednisone—prostate cancer	1.22e-05	0.000103	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—prostate cancer	1.21e-05	0.000103	CcSEcCtD
Ponatinib—Headache—Prednisone—prostate cancer	1.21e-05	0.000102	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.21e-05	0.000102	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—prostate cancer	1.2e-05	0.000102	CcSEcCtD
Ponatinib—Pain—Doxorubicin—prostate cancer	1.19e-05	0.000101	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—prostate cancer	1.19e-05	0.000101	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—prostate cancer	1.19e-05	0.000101	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—prostate cancer	1.19e-05	0.000101	CcSEcCtD
Ponatinib—Nausea—Prednisone—prostate cancer	1.15e-05	9.7e-05	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—prostate cancer	1.14e-05	9.66e-05	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—prostate cancer	1.1e-05	9.34e-05	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—prostate cancer	1.1e-05	9.34e-05	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—prostate cancer	1.08e-05	9.16e-05	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—prostate cancer	1.07e-05	9.03e-05	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—prostate cancer	1.03e-05	8.74e-05	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—prostate cancer	1e-05	8.48e-05	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—prostate cancer	9.98e-06	8.44e-05	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—prostate cancer	9.88e-06	8.36e-05	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—prostate cancer	9.6e-06	8.12e-05	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—prostate cancer	9.56e-06	8.08e-05	CcSEcCtD
Ponatinib—Rash—Epirubicin—prostate cancer	9.52e-06	8.05e-05	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—prostate cancer	9.51e-06	8.04e-05	CcSEcCtD
Ponatinib—Headache—Epirubicin—prostate cancer	9.46e-06	8e-05	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—prostate cancer	9.24e-06	7.81e-05	CcSEcCtD
Ponatinib—Nausea—Epirubicin—prostate cancer	8.97e-06	7.58e-05	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—prostate cancer	8.88e-06	7.51e-05	CcSEcCtD
Ponatinib—Rash—Doxorubicin—prostate cancer	8.81e-06	7.45e-05	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—prostate cancer	8.8e-06	7.44e-05	CcSEcCtD
Ponatinib—Headache—Doxorubicin—prostate cancer	8.75e-06	7.4e-05	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—prostate cancer	8.3e-06	7.02e-05	CcSEcCtD
Ponatinib—ABCB1—Metabolism—LPL—prostate cancer	4.95e-07	4.27e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—prostate cancer	4.95e-07	4.26e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—prostate cancer	4.94e-07	4.26e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—prostate cancer	4.91e-07	4.23e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CREBBP—prostate cancer	4.91e-07	4.23e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—prostate cancer	4.9e-07	4.22e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—prostate cancer	4.9e-07	4.22e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—prostate cancer	4.9e-07	4.22e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—prostate cancer	4.9e-07	4.22e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—prostate cancer	4.89e-07	4.22e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—prostate cancer	4.89e-07	4.21e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—prostate cancer	4.88e-07	4.21e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—prostate cancer	4.88e-07	4.21e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ACHE—prostate cancer	4.88e-07	4.21e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTT1—prostate cancer	4.88e-07	4.21e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—prostate cancer	4.86e-07	4.19e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—prostate cancer	4.85e-07	4.18e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—prostate cancer	4.85e-07	4.18e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1—prostate cancer	4.85e-07	4.18e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1A—prostate cancer	4.84e-07	4.17e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—prostate cancer	4.83e-07	4.16e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—JAK2—prostate cancer	4.83e-07	4.16e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2A6—prostate cancer	4.82e-07	4.16e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TYMS—prostate cancer	4.81e-07	4.15e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—prostate cancer	4.81e-07	4.15e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—prostate cancer	4.8e-07	4.13e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—prostate cancer	4.79e-07	4.13e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP1A1—prostate cancer	4.78e-07	4.12e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—EP300—prostate cancer	4.77e-07	4.12e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—prostate cancer	4.76e-07	4.1e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—prostate cancer	4.75e-07	4.1e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ERCC2—prostate cancer	4.74e-07	4.09e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CAV1—prostate cancer	4.72e-07	4.07e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MDM2—prostate cancer	4.71e-07	4.06e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—prostate cancer	4.7e-07	4.05e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—prostate cancer	4.7e-07	4.05e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—prostate cancer	4.7e-07	4.05e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—INS—prostate cancer	4.7e-07	4.05e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKR1C3—prostate cancer	4.69e-07	4.04e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—prostate cancer	4.69e-07	4.04e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAP2K1—prostate cancer	4.69e-07	4.04e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—prostate cancer	4.67e-07	4.02e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PRKACB—prostate cancer	4.67e-07	4.02e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—LPL—prostate cancer	4.67e-07	4.02e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—prostate cancer	4.66e-07	4.02e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CD—prostate cancer	4.65e-07	4.01e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—prostate cancer	4.65e-07	4.01e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—prostate cancer	4.64e-07	4e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP17A1—prostate cancer	4.62e-07	3.98e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EP300—prostate cancer	4.61e-07	3.97e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SERPINE1—prostate cancer	4.6e-07	3.97e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CREBBP—prostate cancer	4.6e-07	3.97e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—prostate cancer	4.6e-07	3.96e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—prostate cancer	4.59e-07	3.95e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CB—prostate cancer	4.58e-07	3.95e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—prostate cancer	4.56e-07	3.93e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—prostate cancer	4.55e-07	3.92e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—prostate cancer	4.55e-07	3.92e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—prostate cancer	4.54e-07	3.91e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—prostate cancer	4.52e-07	3.9e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—prostate cancer	4.52e-07	3.9e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.51e-07	3.89e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—prostate cancer	4.51e-07	3.89e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP1A1—prostate cancer	4.51e-07	3.89e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SRC—prostate cancer	4.48e-07	3.86e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—prostate cancer	4.48e-07	3.86e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ERCC2—prostate cancer	4.47e-07	3.85e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—prostate cancer	4.46e-07	3.85e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—prostate cancer	4.46e-07	3.84e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGF2—prostate cancer	4.46e-07	3.84e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—prostate cancer	4.45e-07	3.84e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—prostate cancer	4.44e-07	3.83e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—prostate cancer	4.41e-07	3.8e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—prostate cancer	4.4e-07	3.8e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NCOA2—prostate cancer	4.4e-07	3.79e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOS3—prostate cancer	4.39e-07	3.79e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—EP300—prostate cancer	4.38e-07	3.77e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARA—prostate cancer	4.37e-07	3.77e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CD—prostate cancer	4.36e-07	3.76e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—prostate cancer	4.36e-07	3.76e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—prostate cancer	4.34e-07	3.74e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—prostate cancer	4.32e-07	3.72e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—prostate cancer	4.32e-07	3.72e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—prostate cancer	4.31e-07	3.71e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—prostate cancer	4.3e-07	3.71e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1B—prostate cancer	4.3e-07	3.71e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CG—prostate cancer	4.3e-07	3.71e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—prostate cancer	4.29e-07	3.69e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—JAK2—prostate cancer	4.27e-07	3.68e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—prostate cancer	4.22e-07	3.63e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—prostate cancer	4.21e-07	3.63e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—prostate cancer	4.21e-07	3.63e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—prostate cancer	4.21e-07	3.63e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—prostate cancer	4.2e-07	3.62e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.2e-07	3.62e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MDM2—prostate cancer	4.17e-07	3.59e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—prostate cancer	4.16e-07	3.59e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—prostate cancer	4.16e-07	3.59e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—prostate cancer	4.16e-07	3.58e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—prostate cancer	4.15e-07	3.58e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARA—prostate cancer	4.12e-07	3.55e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NOS3—prostate cancer	4.12e-07	3.55e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAV1—prostate cancer	4.11e-07	3.55e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—prostate cancer	4.11e-07	3.54e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—prostate cancer	4.1e-07	3.54e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2E1—prostate cancer	4.1e-07	3.54e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—prostate cancer	4.08e-07	3.52e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—INS—prostate cancer	4.07e-07	3.51e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—prostate cancer	4.07e-07	3.51e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CTNNB1—prostate cancer	4.06e-07	3.5e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CB—prostate cancer	4.06e-07	3.5e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NQO1—prostate cancer	4.06e-07	3.5e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—prostate cancer	4.02e-07	3.47e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—prostate cancer	4.01e-07	3.46e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—prostate cancer	4.01e-07	3.45e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—prostate cancer	4e-07	3.45e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TH—prostate cancer	4e-07	3.45e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—prostate cancer	3.99e-07	3.44e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CREBBP—prostate cancer	3.99e-07	3.44e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—prostate cancer	3.98e-07	3.43e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1A—prostate cancer	3.97e-07	3.42e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—prostate cancer	3.96e-07	3.41e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—prostate cancer	3.95e-07	3.4e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—prostate cancer	3.93e-07	3.39e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—prostate cancer	3.9e-07	3.36e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.89e-07	3.35e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAV1—prostate cancer	3.88e-07	3.34e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—prostate cancer	3.87e-07	3.34e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—prostate cancer	3.86e-07	3.33e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—prostate cancer	3.84e-07	3.31e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—prostate cancer	3.83e-07	3.3e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—prostate cancer	3.83e-07	3.3e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1B—prostate cancer	3.81e-07	3.28e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CB—prostate cancer	3.8e-07	3.28e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CD—prostate cancer	3.78e-07	3.26e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EP300—prostate cancer	3.78e-07	3.26e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—prostate cancer	3.77e-07	3.25e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GGT1—prostate cancer	3.77e-07	3.25e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—prostate cancer	3.75e-07	3.23e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CG—prostate cancer	3.75e-07	3.23e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—prostate cancer	3.74e-07	3.22e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—prostate cancer	3.73e-07	3.22e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—prostate cancer	3.73e-07	3.21e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—prostate cancer	3.71e-07	3.2e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NCOA1—prostate cancer	3.71e-07	3.2e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—prostate cancer	3.68e-07	3.17e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SRC—prostate cancer	3.67e-07	3.17e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.66e-07	3.15e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—prostate cancer	3.63e-07	3.13e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—prostate cancer	3.61e-07	3.12e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CTNNB1—prostate cancer	3.6e-07	3.1e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—prostate cancer	3.58e-07	3.08e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NOS3—prostate cancer	3.57e-07	3.08e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—INS—prostate cancer	3.55e-07	3.06e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—prostate cancer	3.54e-07	3.05e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—prostate cancer	3.53e-07	3.05e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—prostate cancer	3.53e-07	3.04e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CG—prostate cancer	3.53e-07	3.04e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—prostate cancer	3.53e-07	3.04e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—RXRA—prostate cancer	3.53e-07	3.04e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—prostate cancer	3.53e-07	3.04e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1A—prostate cancer	3.51e-07	3.03e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—prostate cancer	3.51e-07	3.02e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CREBBP—prostate cancer	3.47e-07	2.99e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—prostate cancer	3.43e-07	2.96e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—prostate cancer	3.42e-07	2.95e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—prostate cancer	3.41e-07	2.94e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—COMT—prostate cancer	3.4e-07	2.93e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—prostate cancer	3.4e-07	2.93e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—prostate cancer	3.39e-07	2.92e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—prostate cancer	3.38e-07	2.92e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EP300—prostate cancer	3.34e-07	2.88e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—INS—prostate cancer	3.34e-07	2.88e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—prostate cancer	3.33e-07	2.87e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ITPR1—prostate cancer	3.33e-07	2.87e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—prostate cancer	3.3e-07	2.84e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CB—prostate cancer	3.29e-07	2.84e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CD—prostate cancer	3.29e-07	2.84e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—prostate cancer	3.29e-07	2.84e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—prostate cancer	3.29e-07	2.83e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—prostate cancer	3.28e-07	2.83e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CREBBP—prostate cancer	3.27e-07	2.82e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—prostate cancer	3.26e-07	2.81e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—prostate cancer	3.26e-07	2.81e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—prostate cancer	3.24e-07	2.79e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—prostate cancer	3.22e-07	2.77e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—prostate cancer	3.17e-07	2.73e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—prostate cancer	3.16e-07	2.73e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—prostate cancer	3.16e-07	2.72e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TYMS—prostate cancer	3.14e-07	2.71e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—prostate cancer	3.14e-07	2.7e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—EP300—prostate cancer	3.13e-07	2.7e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—prostate cancer	3.13e-07	2.7e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—prostate cancer	3.12e-07	2.69e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NOS3—prostate cancer	3.11e-07	2.68e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—prostate cancer	3.11e-07	2.68e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CD—prostate cancer	3.1e-07	2.68e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LPL—prostate cancer	3.05e-07	2.63e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—prostate cancer	3.04e-07	2.62e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—prostate cancer	3.02e-07	2.6e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.95e-07	2.54e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NOS3—prostate cancer	2.93e-07	2.53e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ERCC2—prostate cancer	2.92e-07	2.52e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—prostate cancer	2.91e-07	2.51e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—prostate cancer	2.91e-07	2.51e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—prostate cancer	2.89e-07	2.49e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CB—prostate cancer	2.87e-07	2.47e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—prostate cancer	2.85e-07	2.46e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—prostate cancer	2.85e-07	2.45e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—prostate cancer	2.84e-07	2.45e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—prostate cancer	2.79e-07	2.41e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—prostate cancer	2.78e-07	2.4e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—prostate cancer	2.75e-07	2.37e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—EP300—prostate cancer	2.72e-07	2.34e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CB—prostate cancer	2.7e-07	2.33e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—prostate cancer	2.7e-07	2.33e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARA—prostate cancer	2.69e-07	2.32e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—prostate cancer	2.69e-07	2.32e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—prostate cancer	2.68e-07	2.31e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—prostate cancer	2.64e-07	2.28e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAV1—prostate cancer	2.53e-07	2.18e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—prostate cancer	2.48e-07	2.14e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—prostate cancer	2.47e-07	2.13e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—prostate cancer	2.47e-07	2.13e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—prostate cancer	2.39e-07	2.06e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—EP300—prostate cancer	2.37e-07	2.04e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—prostate cancer	2.34e-07	2.01e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—prostate cancer	2.32e-07	2e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.31e-07	1.99e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—prostate cancer	2.28e-07	1.97e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—EP300—prostate cancer	2.23e-07	1.92e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—prostate cancer	2.19e-07	1.89e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—INS—prostate cancer	2.18e-07	1.88e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CREBBP—prostate cancer	2.14e-07	1.84e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.03e-07	1.75e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—prostate cancer	2.02e-07	1.74e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—prostate cancer	2.01e-07	1.73e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NOS3—prostate cancer	1.92e-07	1.65e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—prostate cancer	1.89e-07	1.63e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.77e-07	1.52e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—prostate cancer	1.75e-07	1.51e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—prostate cancer	1.75e-07	1.51e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.65e-07	1.42e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—prostate cancer	1.64e-07	1.41e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—prostate cancer	1.53e-07	1.32e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—EP300—prostate cancer	1.46e-07	1.26e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—prostate cancer	1.43e-07	1.23e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—prostate cancer	1.35e-07	1.16e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.08e-07	9.29e-07	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—prostate cancer	8.81e-08	7.59e-07	CbGpPWpGaD
